Pharmaceuticals Search Engine [selected websites]

Tuesday, July 26, 2011

Innovative Health Diagnostics : Results of Its IHD-Amy Blood Tests for Alzheimer’s Disease

July 18, 2011 - PARIS & STRASBOURG, France - Best results obtained to date for a blood test for Alzheimer’s disease with 83% sensitivity and 82% specificity;

Results presented to ICAD (International Conference on Alzheimer’s disease) in Paris on 17th and 18th July

Innovative Health Diagnostics (IHD), the innovative company specialising in the development of diagnostic blood tests for Alzheimer’s disease and neurodegenerative illnesses presents its first clinical results for its IHD-Amy blood test for Alzheimer’s disease.

With the IHD-Amy test, IHD is making it possible to have a diagnostic test based on a peripheral biochemical marker, which is therefore straightforward and economic to carry out, making it one of the most promising ways forward in the research into the diagnosis of Alzheimer’s disease. In addition to this, the fact that this kind of test is carried out at an early stage means that treatment can be followed through far more efficiently, and also means that patient hospitalisation can be delayed. On a longer term basis, this kind of test could be a useful diagnostic tool and a crucial element of the establishment of a proactive public health policy initiative.

The development of these tests is made possible by recent advances in medical knowledge and the discovery of fluorescent probes that can detect proteins that are specific to the disease. Just one drop of blood – 100 to 200 micro litres – is enough to carry out an analysis. These blood tests have the advantage of being quick, minimally invasive, and economic to carry out: just like the IHD-Amy test... Innovative Health Diagnostics' Press Release - communiqué de presse d'Innovative Health Diagnostics -